Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab

Endocrine

Volumn 58, Issue 3, 2017, Pages 535-541

  Brilli, Lucia ^a   Danielli, Riccardo ^a   Ciuoli, Cristina ^a   Calabrò, Luana ^a   Di Giacomo, Anna Maria ^a   Cerase, Alfonso ^b   Paffetti, Patrizia ^a   Sestini, Fausta ^a   Porcelli, Brunetta ^a   Maio, Michele ^a   Pacini, Furio ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

CTLA 4; Hypophysitis; Ipilimumab; Melanoma

Indexed keywords

CORTICOTROPIN; ESTRADIOL; FOLLITROPIN; GROWTH HORMONE; HYDROCORTISONE; IPILIMUMAB; LIVER ENZYME; LUTEINIZING HORMONE; PROLACTIN; SOMATOMEDIN C; TESTOSTERONE; THYROTROPIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COLITIS; CORTICOTROPIN BLOOD LEVEL; ENZYME BLOOD LEVEL; ESTRADIOL BLOOD LEVEL; FATIGUE; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOPHYSITIS; INCIDENCE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MIDDLE AGED; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PRURITUS; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; THYROID FUNCTION TEST; THYROTROPIN RELEASE; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DIAGNOSTIC IMAGING; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PITUITARY FUNCTION TEST; PROSTATE TUMOR;

ADRENOCORTICOTROPIC HORMONE; AGE OF ONSET; AGED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOPHYSITIS; IPILIMUMAB; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; PITUITARY FUNCTION TESTS; PREVALENCE; PROSTATIC NEOPLASMS; THYROTROPIN;

EID: 85017425739     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-017-1289-2     Document Type: Article

References (12)

1. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J.C. Hassel, W. Akerley, A.J. van den Eertwegh, J. Lutzky, P. Lorigan, J.M. Vaubel, G.P. Linette, D. Hogg, C.H. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, J.I. Clark, J.D. Wolchok, J.S. Weber, J. Tian, M.J. Yellin, G.M. Nichol, A. Hoos, W.J. Urba, Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010)
2. S.M. Corsello, A. Barnabei, P. Marchetti, L. De Vecchis, R. Salvatori, F. Torino, Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab. 98, 1361–1375 (2013)
3. A.T. Faje, R. Sullivan, D. Lawrence, N.A. Tritos, R. Fadden, A. Klibanski, L. Nachtigall, Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J. Clin. Endocrinol. Metab. 99, 4078–4085 (2014)
4. M. Ryder, M. Callahan, M.A. Postow, J. Wolchok, J.A. Fagin, Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr. Relat. Cancer. 21, 371–381 (2014)
5. L. Min, F.S. Hodi, A. Giobbie-Hurder, P.A. Ott, J.J. Luke, H. Donahue, M. Davis, R.S. Carroll, U.B. Kaiser, Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin. Cancer Res. 21, 749–755 (2015)
6. F. Albarel, C. Gaudy, F. Castinetti, T. Carré, I. Morange, B. Conte-Devolx, J.J. Grob, T. Brue, Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur. J. Endocrinol. 172, 195–204 (2015)
7. A.M. Di Giacomo, M. Biagioli, M. Maio, The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin. Oncol. 37, 499–507 (2010)
8. S. Iwama, A. De Remigis, M.K. Callahan, S.F. Slovin, J.D. Wolchok, P. Caturegli, Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230ra45 (2014)
9. A.V. Maker, J.C. Yang, R.M. Sherry, S.L. Topalian, U.S. Kammula, R.E. Royal, M. Hughes, M.J. Yellin, L.R. Haworth, C. Levy, T. Allen, S.A. Mavroukakis, P. Attia, S.A. Rosenberg, Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother. 29, 455–463 (2006)
10. A. Faje, Immunotherapy and hypophysitis: clinical presentation, treatment, and biological insights. Pituitary 19, 82–92 (2016)
11. P. Caturegli, G. Di Dalmazi, M. Lombardi, F. Grosso, H.B. Larman, T. Larman, G. Taverna, M. Cosottini, I. Lupi, Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am. J. Pathol. 186, 3225–3235 (2016)
12. A. Ricciuti, A. De Remigis, M.A. Landek-Salgado, L. De Vincentiis, F. Guaraldi, I. Lupi, S. Iwama, G.S. Wand, R. Salvatori, P. Caturegli, Detection of pituitary antibodies by immunofluorescence: approach and results in patients with pituitary diseases. J. Clin. Endocrinol. Metab. 99, 1758–1766 (2014)